152: Building Safer, Smarter, and More Personalized Epilepsy Care

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Building Safer, Smarter, and More Personalized Epilepsy Care," Orrin Devinsky, MD, discusses major areas of progress and ongoing challenges in epilepsy care. Devinsky, a professor in the departments of neurology, neurosurgery, and psychiatry at NYU Grossman School of Medicine, reflects on how the treatment landscape has evolved in recent years, including advances in medication, awareness of SUDEP, and patient counseling. Devinsky also weighs in on the current treatment hierarchy for antiepileptic drugs and whether first-line therapeutic strategies should change. Additional discussion touches on the state of gene therapy development, the need for greater research in disease prevention, the implications of GLP/GIP agents in neurological care, and how neurodevelopmental management is advancing for pediatric patients with epilepsy.

Looking for more Epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page.

Episode Breakdown:

• 0:55 – How epilepsy care has evolved and where progress has been made
• 5:30 – Whether first-line therapy choices for epilepsy should be re-evaluated
• 8:35 – Why gene therapy progress has been slower than expected in epilepsy
• 12:05 – Neurology News Minute
• 14:10 – What areas of epilepsy research deserve greater attention and funding
• 17:10 – How GLP/GIP agents could intersect with neurological and epilepsy care
• 20:00 – How clinicians can better address neurodevelopmental challenges in patients with epilepsy

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Neflamapimod Advances to Phase 3 Trial in Dementia With Lewy Bodies After Positive RewinD-LB Results

• FDA Delays Review Deadline for Hunter Syndrome Agent Tividenofusp Alfa

• FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.